Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 15/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.50 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.50 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 4/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6328925 | 0.83 | TGFBR1 (0.67) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL6402931 | 0.81 | TGFBR1 (0.63) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL6223211 | 0.80 | TGFBR1 (0.54) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL6226473 | 0.80 | TGFBR1 (0.62) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL6332298 | 0.79 | TGFBR1 (0.61) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL5956506 | 0.78 | TGFBR1 (0.46) | TGFBR1MAPK14RIPK2ACVR1BKDR | |
| SCHEMBL6251764 | 0.76 | TGFBR1 (0.57) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL5956501 | 0.76 | TGFBR1 (0.56) | TGFBR1MAPK14KDRACACA | |
| SCHEMBL6248273 | 0.75 | TGFBR1 (0.58) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL6264300 | 0.74 | TGFBR1 (0.78) | TGFBR1MTORMAPK14RIPK2ACVR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245520-A1 | 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors | DODIC NERINA | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245520-A1 | 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors | SMAD2, SMAD3, ALK | TGFBR1 7/4885MTOR 77/4885MAPK14 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.